Health-related quality of life as an endpoint in oncology phase I trials: a systematic review

BACKGROUND: Phase I trials aim to identify the recommended dose for further development. Health-related quality of life (HRQoL) could be a complement to the usual National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) scale to detect adverse events and define the doses....

Descripción completa

Detalles Bibliográficos
Autores principales: Fiteni, Frédéric, Ray, Isabelle Le, Ousmen, Ahmad, Isambert, Nicolas, Anota, Amélie, Bonnetain, Franck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469065/
https://www.ncbi.nlm.nih.gov/pubmed/30991990
http://dx.doi.org/10.1186/s12885-019-5579-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469065/
https://www.ncbi.nlm.nih.gov/pubmed/30991990
http://dx.doi.org/10.1186/s12885-019-5579-3

Ejemplares similares